GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Dr. Lal PathLabs Ltd (NSE:LALPATHLAB) » Definitions » Return-on-Tangible-Equity

Dr. Lal PathLabs (NSE:LALPATHLAB) Return-on-Tangible-Equity : 33.92% (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Dr. Lal PathLabs Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Dr. Lal PathLabs's annualized net income for the quarter that ended in Mar. 2024 was ₹3,381 Mil. Dr. Lal PathLabs's average shareholder tangible equity for the quarter that ended in Mar. 2024 was ₹9,968 Mil. Therefore, Dr. Lal PathLabs's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 was 33.92%.

The historical rank and industry rank for Dr. Lal PathLabs's Return-on-Tangible-Equity or its related term are showing as below:

NSE:LALPATHLAB' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 24.33   Med: 33.87   Max: 42.5
Current: 40.48

During the past 13 years, Dr. Lal PathLabs's highest Return-on-Tangible-Equity was 42.50%. The lowest was 24.33%. And the median was 33.87%.

NSE:LALPATHLAB's Return-on-Tangible-Equity is ranked better than
79.08% of 196 companies
in the Medical Diagnostics & Research industry
Industry Median: -2.175 vs NSE:LALPATHLAB: 40.48

Dr. Lal PathLabs Return-on-Tangible-Equity Historical Data

The historical data trend for Dr. Lal PathLabs's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dr. Lal PathLabs Return-on-Tangible-Equity Chart

Dr. Lal PathLabs Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.00 29.01 41.85 36.52 40.72

Dr. Lal PathLabs Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 29.80 43.46 48.91 36.38 33.92

Competitive Comparison of Dr. Lal PathLabs's Return-on-Tangible-Equity

For the Diagnostics & Research subindustry, Dr. Lal PathLabs's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dr. Lal PathLabs's Return-on-Tangible-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Dr. Lal PathLabs's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Dr. Lal PathLabs's Return-on-Tangible-Equity falls into.



Dr. Lal PathLabs Return-on-Tangible-Equity Calculation

Dr. Lal PathLabs's annualized Return-on-Tangible-Equity for the fiscal year that ended in Mar. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Mar. 2024 )  (A: Mar. 2023 )(A: Mar. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Mar. 2024 )  (A: Mar. 2023 )(A: Mar. 2024 )
=3577.35/( (7602.67+9967.88 )/ 2 )
=3577.35/8785.275
=40.72 %

Dr. Lal PathLabs's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=3381.4/( (0+9967.88)/ 1 )
=3381.4/9967.88
=33.92 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Dr. Lal PathLabs  (NSE:LALPATHLAB) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Dr. Lal PathLabs Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Dr. Lal PathLabs's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Dr. Lal PathLabs (NSE:LALPATHLAB) Business Description

Traded in Other Exchanges
Address
12th Floor, Tower B, SAS Tower, Sector 38, Medicity, Gurugram, HR, IND, 122 001
Dr. Lal PathLabs Ltd is a pathology lab based in India. It is involved in providing diagnostic services and other healthcare tests in the area of pathology and radiology. The company operates laboratories for carrying out pathological diagnostic services in various branches of biochemistry, hematology, histopathology, microbiology, electrophoresis, immunochemistry, immunology, virology, cytology, and other pathological and radiological investigations. Its diagnostic services assist to prevent, monitor and treat diseases and improving health conditions. The company has business operations in India and other countries, of which maximum revenue is generated within India.

Dr. Lal PathLabs (NSE:LALPATHLAB) Headlines

No Headlines